BioLife Solutions, Inc. (BLFS)

Market Cap	1.03B
Revenue (ttm)	87.76M
Net Income (ttm)	-10.41M
Shares Out	47.56M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	4,199.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	480,524
Open	21.26
Previous Close	21.54
Day's Range	21.26 - 22.39
52-Week Range	18.70 - 29.55
Beta	1.79
Analysts	Strong Buy
Price Target	30.57 (+41.14%)
Earnings Date	Aug 7, 2025

About BLFS

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduc...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Nov 22, 1989
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: BLFS
• Website: https://www.biolifesolutions.com

Financial Performance

In 2024, BioLife Solutions's revenue was $82.25 million, an increase of 8.44% compared to the previous year's $75.86 million. Losses were -$20.18 million, -70.32% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for BLFS stock is "Strong Buy." The 12-month stock price target is $30.57, which is an increase of 41.14% from the latest price.

Price Target

$30.57

(41.14% upside)

Analyst Consensus: Strong Buy